Name (Synonyms) | Correlation | |
---|---|---|
drug326 | Behavioral Activation in real-life Wiki | 1.00 |
There is one clinical trial.
The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD). The secondary purpose of this study is to examine whether any evidence of clinical efficacy exists for VR delivered BA.
Description: This outcome will be measured using the "Intention to use Technology " questions of the Technology Acceptance Model questionnaire. These are questions 11, 12, and 13 and allow participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.
Measure: Participant's desire to continue using VR after the study ends Time: 4-weeksDescription: Participant treatment dropout will be compared across each study arm.
Measure: Rates of dropout of VR-BA Time: 4-weeksDescription: This outcome will be measured using the "Attitudes Toward Use " questions of the Technology Acceptance Model questionnaire. These are questions 7, 8, 9, and 10 and allow participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.
Measure: Participant's satisfaction with the VR-BA treatment Time: 4-weeksDescription: This will be measured by noting the amount of times the VR headset is used.
Measure: Participant's use of the VR headset Time: 4-weeksDescription: This will be measured using the overall Technology Acceptance Model questionnaire, which encompasses 13 questions and allows participants the option of circling Strongly Disagree, Disagree, Neutral, Agree, or Strongly Agree.
Measure: Participant's acceptance of VR-BA treatment Time: 4-weeksDescription: This will be determined by the Simulator Sickness Questionnaire, which names 16 adverse symptoms and asks participants to circle as compared to baseline: No more than usual, Slightly more than usual, Moderately more than usual, or Severely more than usual.
Measure: How well can participants tolerate the VR-BA treatment? Time: 4-weeksDescription: This will be measured using the Presence Questionnaire, which asks three questions and asks the participants to circle either Not at all, Slightly, Moderately, Strongly, or Very Strongly.
Measure: How present did individuals in the VR-BA treatment feel? Time: 4-weeks.Description: How participants' depression scores PHQ-9 change over time using VR-BA compared to BA in real life and a waitlist control. The PHQ-9 is a 9-question screener with a score range of 0-29, with 29 indicating the most severe depression and 0 indicating a lack of depression symptoms.
Measure: Clinical efficacy of using VR as a tool to deliver BA Time: 4-weeks